Citius Pharmaceuticals (CTXR) Non Operating Income (2011 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Non Operating Income came in at $3.9 million in Q1 2026, up 28632.05% YoY from N/an in Q1 2025, and up 3589.49% on a QoQ basis from -$110441.0 in Q4 2025.
Citius Pharmaceuticals (CTXR) Non Operating Income (2011 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 15 years of Non Operating Income data on file, last reported at $3.9 million in Q1 2026.
- Quarterly Non Operating Income rose 28632.05% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 891.03% YoY) and the FY2025 annual result came in at -$157701.0, down 105.01% from the prior year.
- Non Operating Income climbed to $3.9 million in Q1 2026, from -$110441.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $3.9 million in Q1 2026 to a low of -$151625.0 in Q2 2025.
- A 5-year average of $821188.3 and a median of $229240.5 in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2025 — Non Operating Income tumbled 588.5% — and 2026, when it surged 28632.05%.
- Tracing CTXR's Non Operating Income over 5 years: stood at $3.8 million in 2022, then tumbled by 93.33% to $253638.0 in 2023, then slumped by 91.09% to $22608.0 in 2024, then plunged by 588.5% to -$110441.0 in 2025, then surged by 3589.49% to $3.9 million in 2026.
- The last three Non Operating Income figures came in at $3.9 million (Q1 2026), -$110441.0 (Q4 2025), and -$42097.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Citius Pharmaceuticals | 15.71 Mn | 15.71 Mn | 1.00 Mn | -294,533.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.85 Mn |
| Dec 31, 2025 | -110,441.00 |
| Sep 30, 2025 | -42,097.00 |
| Jun 30, 2025 | -151,625.00 |
| Mar 31, 2025 | 13,413.00 |
| Dec 31, 2024 | 22,608.00 |
| Sep 30, 2024 | 117,314.00 |
| Jun 30, 2024 | 204,843.00 |
| Mar 31, 2024 | 2.57 Mn |
| Dec 31, 2023 | 253,638.00 |
| Sep 30, 2023 | 324,813.00 |
| Jun 30, 2023 | 336,780.00 |
| Mar 31, 2023 | 303,275.00 |
| Dec 31, 2022 | 3.80 Mn |
| Sep 30, 2021 | 242,158.00 |
| Jun 30, 2021 | 160,398.00 |
| Mar 31, 2021 | 65,388.00 |
| Dec 31, 2020 | 9,516.00 |
| Sep 30, 2020 | 20,146.00 |
| Jun 30, 2020 | 8,773.00 |